Marilyn Borgman.

John Chapman, Ph.D., D.Sc., Raimund M. Erbel, M.D., Peter Libby, M.D., Joel S. Raichlen, M.D., Kiyoko Uno, M.D., Marilyn Borgman, R.N., Kathy Wolski, M.P.H., and Steven E. Nissen, M.D.: Effect of Two Intensive Statin Regimens on Progression of Coronary Disease Randomized medical trials have consistently shown that inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase reduce cardiovascular event prices.1-9 The favorable effects of statins extend across a range of degrees of low-density lipoprotein cholesterol, with no apparent lower threshold for a benefit.3,9,10 In parallel, imaging trials show that intensive statin regimens slow the progression of coronary atherosclerosis and may even result in disease regression in a few sufferers.11,12 Accordingly, guidelines for coronary disease prevention possess increasingly emphasized that lowering LDL cholesterol levels with statins may be the main aim of lipid-modulating therapy.The choice between local and general anesthesia for transfemoral implantation was still left up to the average person team. Study End Points The principal end point was loss of life from any cause at 1 month, 6 months, and 1, 2, 3, 4, and 5 years. Secondary protection end points were major adverse cardiovascular or cerebrovascular events, cardiac events, cardiac or vascular surgery, bleeding or stroke during follow-up, and NYHA practical class. Secondary efficacy end points were the success price and complications based on Valve Academic Study Consortium criteria,24 with periodic echocardiographic assessment of aortic-valve function during the 1st 3 years, including evaluation of the mean valve and gradient area, in addition to assessment for the severe nature and presence of aortic-valve or mitral-valve regurgitation.